Examining the metastatic niche: targeting the microenvironment.

Research output: Contribution to journalReview article

92 Citations (Scopus)

Abstract

Some of the most common cancer types, including breast cancer, prostate cancer, and lung cancer, show a predilection to metastasize to bone. The molecular basis of this preferential growth of cancer cells in the bone microenvironment has been an area of active investigation. Although the precise molecular mechanisms underlying this process remain to be elucidated, it is now increasingly being recognized that the unique characteristics of the bone niche provide homing signals to cancer cells, and create a microenvironment conducive for the cancer cells to colonize. Concomitantly, cancer cells release several regulatory factors that result in abnormal bone destruction and/or formation. This complex bidirectional interplay between tumor cells and bone microenvironment establishes a "vicious cycle" that leads to a selective growth advantage for the cancer cells. The molecular insights gained on the underpinnings of bone metastasis in recent years have also provided us with avenues to devise innovative approaches for therapeutic intervention. The goal of this review is to describe our current understanding of molecular pathophysiology of cancer metastases to bone, as well as its therapeutic implications.

Original languageEnglish (US)
Pages (from-to)S2-14
JournalSeminars in oncology
Volume37 Suppl 2
StatePublished - Oct 2010

Fingerprint

Bone and Bones
Neoplasms
Lung Neoplasms
Prostatic Neoplasms
Breast Neoplasms
Neoplasm Metastasis
Cellular Microenvironment
Tumor Microenvironment
Growth
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Examining the metastatic niche : targeting the microenvironment. / Guise, Theresa.

In: Seminars in oncology, Vol. 37 Suppl 2, 10.2010, p. S2-14.

Research output: Contribution to journalReview article

@article{16c525ad61a84527997d2ff93d06a62c,
title = "Examining the metastatic niche: targeting the microenvironment.",
abstract = "Some of the most common cancer types, including breast cancer, prostate cancer, and lung cancer, show a predilection to metastasize to bone. The molecular basis of this preferential growth of cancer cells in the bone microenvironment has been an area of active investigation. Although the precise molecular mechanisms underlying this process remain to be elucidated, it is now increasingly being recognized that the unique characteristics of the bone niche provide homing signals to cancer cells, and create a microenvironment conducive for the cancer cells to colonize. Concomitantly, cancer cells release several regulatory factors that result in abnormal bone destruction and/or formation. This complex bidirectional interplay between tumor cells and bone microenvironment establishes a {"}vicious cycle{"} that leads to a selective growth advantage for the cancer cells. The molecular insights gained on the underpinnings of bone metastasis in recent years have also provided us with avenues to devise innovative approaches for therapeutic intervention. The goal of this review is to describe our current understanding of molecular pathophysiology of cancer metastases to bone, as well as its therapeutic implications.",
author = "Theresa Guise",
year = "2010",
month = "10",
language = "English (US)",
volume = "37 Suppl 2",
pages = "S2--14",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Examining the metastatic niche

T2 - targeting the microenvironment.

AU - Guise, Theresa

PY - 2010/10

Y1 - 2010/10

N2 - Some of the most common cancer types, including breast cancer, prostate cancer, and lung cancer, show a predilection to metastasize to bone. The molecular basis of this preferential growth of cancer cells in the bone microenvironment has been an area of active investigation. Although the precise molecular mechanisms underlying this process remain to be elucidated, it is now increasingly being recognized that the unique characteristics of the bone niche provide homing signals to cancer cells, and create a microenvironment conducive for the cancer cells to colonize. Concomitantly, cancer cells release several regulatory factors that result in abnormal bone destruction and/or formation. This complex bidirectional interplay between tumor cells and bone microenvironment establishes a "vicious cycle" that leads to a selective growth advantage for the cancer cells. The molecular insights gained on the underpinnings of bone metastasis in recent years have also provided us with avenues to devise innovative approaches for therapeutic intervention. The goal of this review is to describe our current understanding of molecular pathophysiology of cancer metastases to bone, as well as its therapeutic implications.

AB - Some of the most common cancer types, including breast cancer, prostate cancer, and lung cancer, show a predilection to metastasize to bone. The molecular basis of this preferential growth of cancer cells in the bone microenvironment has been an area of active investigation. Although the precise molecular mechanisms underlying this process remain to be elucidated, it is now increasingly being recognized that the unique characteristics of the bone niche provide homing signals to cancer cells, and create a microenvironment conducive for the cancer cells to colonize. Concomitantly, cancer cells release several regulatory factors that result in abnormal bone destruction and/or formation. This complex bidirectional interplay between tumor cells and bone microenvironment establishes a "vicious cycle" that leads to a selective growth advantage for the cancer cells. The molecular insights gained on the underpinnings of bone metastasis in recent years have also provided us with avenues to devise innovative approaches for therapeutic intervention. The goal of this review is to describe our current understanding of molecular pathophysiology of cancer metastases to bone, as well as its therapeutic implications.

UR - http://www.scopus.com/inward/record.url?scp=79952111472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952111472&partnerID=8YFLogxK

M3 - Review article

C2 - 21111245

AN - SCOPUS:79952111472

VL - 37 Suppl 2

SP - S2-14

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

ER -